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Summary Osteopontin (OPN) produced by alveolar macrophages functions as a
fibrogenic cytokine in the development of bleomycin (BLM)-induced murine
pulmonary fibrosis, and OPN mRNA is expressed on lung tissues from patients with
idiopathic pulmonary fibrosis (IPF). The present study investigates plasma OPN levels
in human interstitial pneumonia (IP) and their relationships with disease severity by
analyzing the correlation between plasma OPN concentrations and pulmonary
functions. The concentrations of OPN in plasma were measured in 17 patients with
IP, in 9 with sarcoidosis and in 20 healthy controls using an antigen-capture enzyme-
linked immunosorbent assay. The concentrations of OPN in plasma were significantly
higher in IP patients than in those with sarcoidosis or in controls. Based on a Receiver
Operating Characteristic curve analysis, cut-off points between 300 and 380 ng/ml
discriminated between IP and control subjects with 100% sensitivity and 100%
specificity. In such case, the sensitivity for sarcoidosis decreased (55.5–33.3%) in cut-
offs with 100% specificity. Plasma OPN levels inversely and closely correlated with
arterial oxygen tension (PaO2) in patients with IP. Immunohistochemically, OPN was
localized predominantly in macrophages and airway epithelium. These findings
suggest that plasma OPN levels were found to be associated with the presence of IP,
and that OPN play an important role in the development of IP.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
Osteopontin (OPN, also known as Eta-1) is a
phosphorylated acidic glycoprotein secreted by a
variety of cells including osteoclasts, activated T
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arginine–glycine–aspartate (RGD)-binding motif
that binds to the integrin family of adhesion
molecules2,3 and it functions as a proinflammatory
cytokine that causes cellular adhesion and chemo-
taxis of different cell types, such as inflammatory
leukocytes and vascular smooth muscle cells.4–6 In
this context, some investigators have identified a
biological role of OPN in the pathogenesis of various
diseases. For example, OPN is expressed by
infiltrating macrophages in experimental cardiac
injury and myocardial infarction,7 and it is also
involved in the pathogenesis of glomerulonephritis
as well as in the angiogenesis of cancer cells.8,9
The potential role of OPN in the pathogenesis of
pulmonary granulomatous diseases such as tuber-
culosis, silicosis and sarcoidosis is of interest.
Macrophages and Tcells produce abundant amounts
of OPN during the granuloma formation associated
with tuberculosis, Mycobacterium avium-intracel-
lulare infection, silicosis and sarcoidosis.10–12
Furthermore, OPN is involved in lung injury. We
demonstrated that OPN mRNA is overexpressed on
alveolar macrophages in the lungs of transgenic
mice that express tumor necrosis factor (TNF)-a in
type II pneumocytes, leading to pulmonary alveo-
litis and progressive fibrosis.13,14 In addition, OPN
produced by alveolar macrophages functions as a
fibrogenic cytokine that promote migration, adhe-
sion, and proliferation of fibroblasts in the devel-
opment of bleomycin (BLM)-induced murine
pulmonary fibrosis.15 In human, mRNA from lung
biopsies of patients with idiopathic pulmonary
fibrosis (IPF) was subjected to cDNA microarray
analysis, and similar to murine lung fibrosis induced
by bleomycin, OPN was among the most promi-
nently expressed cytokines when compared to
normal lung.16 Collectively these findings suggest
that OPN play a key role in the development of
pulmonary alveolitis leading to fibrosis.
In this study we have measured plasma OPN
levels in patients with interstitial pneumonia (IP)
and examined their relationship with disease




We studied 11 male and 6 female patients with IP of
mean (7 SD) age 59 (7 16) years, whose conditions
included idiopathic pulmonary fibrosis (IPF; n¼ 8),
idiopathic nonspecific interstitial pneumonia (NSIP;
n¼ 2), cryptogenic organizing pneumonia (COP;
n¼ 2), giant cell interstitial pneumonia (GIP;
n¼ 1), collagen vascular disease-associated IP
(CVD-IP; n¼ 3; each patient had rheumatoid
arthritis, mixed connective tissue disease or der-
matomyositis) and drug-induced IP (n¼ 1). Each
patient with NSIP or COP was receiving therapy
with 10mg of corticosteroid and none of the
remaining patients had received corticosteroids or
other immunomodulators at the time of peripheral
blood collection. We also studied 5 male and 4
female patients of mean age 53 (715) years with
sarcoidosis at stage I in 3 patients, II in 5 and III in 1.
None of these patients were medicated with
corticosteroids or other immunomodulators at the
time of plasma sample collection. Patients with
cancer, those suspected of having a malignancy or
those with cardiovascular diseases were excluded
from the study since elevated OPN levels in
peripheral blood samples of these diseases have
been demonstrated.17,18 Malignancies were unde-
tectable in any of the patients throughout the
study. Plasma samples were also collected from 10
healthy male and 10 healthy female volunteers
(mean age, 58 (716) years) with no history of IP or
other interstitial lung diseases, and whose chest
radiographs showed no evidence of respiratory
diseases. All participants provided written, in-
formed consent to participate in the study.
Study design
Peripheral blood was collected into tubes contain-
ing EDTA, and plasma samples were stored at
801C. Serum samples were simultaneously ob-
tained to measure KL-6, surfactant protein (SP)-A
and SP-D. Pulmonary function test was tested and
blood gas was analyzed at the time of or within one
month before and after peripheral blood sampling.
OPN, KL-6, SP-A and SP-D levels
Plasma OPN concentrations were measured by an
antigen-capture enzyme-linked immunosorbent as-
say (ELISA) using a commercially available kit
(Human OPN assay kit, Immuno-Biological Labora-
tories Co., Gunma, Japan). This ELISA kit was
recently developed based on the method reported
by Kon et al.19 The sensitivity of the assay was 5 ng/
ml. We measured levels of each marker using
specific kits according to the protocols provided
by the manufacturers. KL-6 concentrations were
measured using a sandwich-type electrochemilumi-
nescence immunoassay (ECLIA) kit (Picolumi KL-6;
Sanko Junyaku Co., Tokyo, Japan). SP-A and SP-D
levels were measured using sandwich-type enzyme
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immunoassay (EIA) kits (SP-A test-F; Kokusai Shiya-
ku Co., Hyogo, Japan and SP-D kit Yamasa; Yamasa
Shoyu Co., Tokyo, Japan, respectively). Serum cut
off values were established at 500U/ml for KL-6
43.8 ng/ml for SP-A, 110 ng/ml for SP-D. All assays
were performed in duplicate.
Immunohistochemistry of lung tissues
Immunohistochemical analysis of OPN in the lungs
of patients with IPF or with NSIP was performed.
Surgical lung biopsy specimens were obtained from
two IPF patients and two NSIP patients. Control
specimens were obtained from the normal parts of
lungs removed for lung cancer. Briefly, after
deparaffinization and rehydration tissue sections
(5 mm thick) were treated with pronase for 5min
(DAKO Corporation, Carpinteria, CA), followed by
3% hydrogen peroxide in methanol for 20min to
inactivate endogenous peroxidases. Lung sections
were incubated with non-specific staining blocking
reagent (DAKO) for 10min, followed by overnight
incubation at 41C with primary monoclonal anti-
OPN antibody (MPIIIB10; developmental studies,
hybridoma bank, University of Iowa, Iowa City, IA)
at a concentration of 1:300 in a moist chamber. The
immunoreaction product was detected with the
ENVISION system (DAKO) and with diaminobenzi-
dine as the chromogen. The sections were counter-
stained with hematoxylin. The primary antibody
was replaced by normal mouse IgGl for negative
control slides.
Statistical analysis
All values were expressed as mean7SD values. Data
were statistically analyzed using StatView-J 5.0
software (Abacus Concept, Inc., Berkeley, CA).
Differences between groups were examined using
the ANOVA test with a post-hoc analysis (Fisher’s
PLSD test). Correlations between two defined
parameters were determined using the Spearman’s




We compared plasma OPN concentrations among
patients with IP, patients with sarcoidosis and
healthy controls. Fig. 1 shows that plasma OPN
concentrations in patients with IP were significantly
higher than in controls and in patients with
sarcoidosis (945.57256.0 ng/ml vs 156.7752.2
and 321.27146.8 ng/ml; Po0.0001, respectively).
Plasma OPN concentrations of the latter group
were also significantly higher than in the controls
(Po0.05). No significant difference was observed in
the levels of plasma OPN between IPF and other IP
(data not shown). Based on a Receiver Operating
Characteristic (ROC) curve analysis (Fig. 2), cut-off
points between 300 and 380 ng/ml discriminated
between IP and control subjects with 100% sensi-
tivity and 100% specificity. In such case, the
sensitivity for sarcoidosis decreased (55.5–33.3%)
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Figure 1 Plasma OPN concentrations in patients with
interstitial pneumonia, sarcoidosis, and healthy controls.
Plasma OPN levels were compared among controls (C),
and patients with sarcoidosis (Sa) and interstitial
pneumonia (IP).
Figure 2 Receiver Operating Characteristic (ROC) curve
for plasma OPN levels in patients with IP or with
sarcoidosis.
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in cut-offs with 100% specificity. Plasma OPN levels
did not significantly differ between males and
female or between smokers and nonsmokers in
the control and patient groups. In addition, OPN
levels did not increase with age (data not shown).
Plasma OPN concentrations inversely and closely
correlated with the value of PaO2, but not with
either %VC or %TLCO in patients with IP (Fig. 3 and
Table 1). A correlation analysis of the levels of KL-
6, SP-A, and SP-D (markers of disease activity in
interstitial lung diseases) with these clinical para-
meters revealed significant correlations only be-
tween KL-6 and %VC (Table 1). Plasma OPN levels
and the serum concentrations of KL-6, SP-A, or SP-D
did not significantly correlate in patients with IP
(data not shown).
Immunostaining of OPN
Immunohistochemical study in two patients with
IPF using anti-OPN antibody demonstrated high
levels of immunoreactivity for OPN both in the
alveolar and interstitial cells of macrophage mor-
phology in contrast to no expression in lymphocytes
(Fig. 4a, b). A strong OPN signal was also detected
in airway epithelium (Fig. 4a). Similar staining for
OPN was observed in sections from two patients
with NSIP (Fig. 4d, e). No staining was seen with the
isotype control (Fig. 4c, f). In control lung tissue
alveolar macrophages and airway epithelium also
exhibited OPN staining; however, this was less than
that seen in IPF and NSIP.
Discussion
The role of OPN on pulmonary fibrosis or IP has been
demonstrated in an experimental mouse model.
OPN gene and protein were expressed mainly on
alveolar macrophages in the mouse lung after the
administration of BLM15 or in the TNF-a transgenic
mouse lung13,14 in parallel with the infiltration of
inflammatory cells and thickening of alveolar walls
and with subsequent pulmonary fibrosis. OPN is
expressed during inflammatory alveolitis, yet levels
continue to increase and peak at stages of fibrosis
when inflammatory infiltrates have receded.13–15,20
A study in vitro also demonstrated the cell adhesion
and migration of fibroblasts mediated by OPN.15
These observations suggest that OPN is involved in
the pathogenesis of lung injury.
However, the relationship between OPN and IP in
humans has not been fully evaluated. The signifi-
cantly higher plasma levels of OPN in patients with
IP relative to those in patients with sarcoidosis or
healthy controls support this supposition. In addi-
tion, when the cut-off value was set between 300
and 380 ng/ml based on a ROC curve, the levels of
OPN in plasma reliably distinguished IP case
patients from control subjects. Thus, plasma OPN
levels were found to be associated with the
presence of IP.
High plasma OPN levels significantly correlated
with arterial oxygen tension, a clinical parameter
indicative of disease severity. The present immu-
nohistochemical study demonstrated that a strong
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Figure 3 Correlation between plasma OPN concentra-
tions and arterial oxygen tension in patients with IP
(n¼ 15). Each symbol indicates one patient. Plasma OPN
concentrations inversely correlated with PaO2 values
(r¼0.734, P¼ 0.0080).
Table 1 Correlation between concentrations of osteopontin, KL-6, SP-A, and SP-D and pulmonary function
indicators.
PaO2 (Torr) % VC % TLCO
Osteopontin R¼0.734 (P¼ 0.0080) NS NS
KL-6 NS R¼0.648 (P¼ 0.0289) NS
SP-A NS NS NS
SP-D NS NS NS
PaO2, arterial oxygen tension; VC, vital capacity; TLCO, carbon monoxide transfer factor; NS, not significant
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OPN signal was detected in macrophages and
airway epithelium in human IP, while not in
lymphocytes. Normal lung did not show significant
staining for OPN. This was similar to the findings
previously reported by Nau et al. that OPN staining
of airway epithelium is seen in inflamed but not
normal lung.10 Additionally, using cDNA microarray
analysis OPN mRNA from lung biopsies of patients
with IPF was among the most prominently ex-
pressed cytokines when compared to normal lung
removed for lung cancer.16 These studies suggest
the local production of OPN in the lung of human IP.
OPN mediates the migration, proliferation and
adhesion of fibroblasts in the alveolar paace, which
are essential for the initial process of pulmonary
fibrosis.15 Ultrastructural studies during the early
stages of pulmonary fibrosis have shown that
fenestrations develop in the alveolar capillary
endothelial cells and that gaps form in the
epithelial basement membrane.21 Thus, the high
plasma OPN levels identified in the present study
might relate to leakage that is accelerated as a
result of damage to the air–blood barrier in lung
parenchyma, and the inverse relationship between
plasma OPN concentrations and PaO2 might reflect
the initial or early stage of the fibrotic process in
the lung. Collectively our finding suggests that
similar to murine lung fibrosis, OPN play an
important role in the development of IP.
Plasma OPN concentrations in patients with
sarcoidosis were also significantly higher compared
with controls, but to a lesser extent than those of
patients with IP. Sarcoid granulomas exhibit a
characteristic pattern of strong lymphocyte-asso-
ciated OPN staining, and the late fibrotic granulo-
mas exhibit significant less OPN expression, which
was limited to multinucleated giant cells.11 These
data demonstrate that OPN expression is more
pronounced in the early cellular granulomas of
sarcoidosis and that this pattern of expression is
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Figure 4 Immunohistochemical stain of OPN in IPF, NSIP and normal lung. (a–c), IPF. (d–f), NSIP. Magnification x 400.
Note strong OPN staining (brown) in alveolar macrophages (black arrow) and airway epithelium (white arrow) and no
detectable OPN signal in lymphocytes (arrow head) (a, b, d, and e). (g) and (h), normal lung. Magnification x 400. Note
weak alveolar macrophage- and airway epithelium-associated staining for OPN. (c) and (f), No staining with isotype
control.
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distinct from that seen in IP, indicating that plasma
OPN levels in sarcoidosis may vary with the stage.
KL-6, SP-A and D are biomarkers of IP.22,23
However, the present study found no relationships
between these markers and pulmonary function
tests including PaO2 except for KL-6 and %VC. These
findings confirmed that these three markers are not
correlated with pulmonary function indicators in
patients with IPF, including PaO2, %VC and %TLCO
except for SP-A, %VC and %TLCO,24 and that serum
levels of neither SP-A nor SP-D correlated with %VC
or %TLCO.23 Additionally, our study could not find any
correlation between plasma OPN levels and serum
concentrations of KL-6, SP-A or SP-D (data not
shown), probably because of differences in the
origins of these markers. KL-6 derives from da-
maged or regenerating type II pneumocytes in IPF,25
whereas SP-A and D are produced by two types of
epithelial cells in the peripheral airway, namely
Clara cells and alveolar type II cells.23 These
findings suggest that serum concentrations of KL-
6, SP-A, and SP-D rather reflect the later stage
(remodeling stage) of the process of fibrosis.
In conclusion, our study might be the first to show
that plasma concentrations of OPN are increased in
patients with IP and inversely correlated with
arterial oxygen tension. OPN expression was also
evident in macrophages and airway epithelium. Our
findings suggest that the plasma OPN levels were
found to be associated with the presence of IP, and
that OPN play an important role in the develop-
ment of IP. However, as our study included several
types of IP and recent several reports have
demonstrated the high OPN levels in cancer and
in pulmonary tuberculosis,17,26 further evaluations
are necessary to elucidate the potential of OPN in
the clinical management of IP.
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